good question, i'm guessing it shrinks at the target tissue dies and it reshapes itself after all the healing is done. i cant imagine it will look like swiss cheese after!
Fexapotide TRriflutate is a protein injectable for benign prostatic
hyperplasia (prostate enlargement, "BPH") and for low grade localized
prostate cancer. It has been designed to be administered in the urologist's
office in a simple injection that takes a few minutes. FT is a new molecular
entity which safely targets prostate glandular cells that have proliferated in
BPH. FT works by a mechanism of inducing apoptosis (programmed cell death)
which selectively removes cells in the enlarged BPH prostate gland, and that
also is useful in removing low grade localized early stage prostate cancers.
In research studies, FT is associated with increased expression of
important apoptosis markers, and all of the cellular signs of the hallmarks of
apoptotic cell loss. FT has remarkable selectivity for the overgrowth of the
prostate gland cells in BPH and in low grade localized prostate cancer. Studies
of FT's cellular effects, metabolism and kinetics have shown that FT does not
have any effects on nearby structures or on important distant organs. Repeated
injections of FT do not induce any discernible immune reaction in patients,
which is another important reason for FT's excellent safety results. In
large clinical trials involving over 1700 men there have been minimal side
effects from FT.
Long-term studies of FT involving 997 enrolled patients followed for up to
7 years showed statistically significant lasting improvement in BPH symptom
scores compared to placebo controls. The symptom scores reflect improvements in
urgency, frequency, nocturia, poor urinary flow, stopping and starting,
incomplete emptying, and straining. Long-term studies also showed that patients
who received 1 or 2 injections of FT had significantly less need for invasive
BPH surgical interventions than control patients who did not receive FT. The
clinical trials also demonstrated improvements in sexual function in patients
given FT. FT treatment led to lower incidence of the need for bladder
catheterization, and none of the typical side effects associated with current
drug treatments.
FT works by a mechanism of inducing apoptosis (programmed cell death) which
selectively removes cells in the enlarged BPH prostate gland, and that also is
useful in removing low grade localized early stage prostate cancers. In
research studies, FT is associated with increased expression of important
apoptosis markers, and all of the cellular signs of the hallmarks of apoptotic
cell loss. In large clinical trials involving over 1700 men there have been
minimal side effects from FT, which is based on FT's remarkable selectivity for
the overgrowth of the prostate gland cells in BPH and in low grade localized
prostate cancer. Studies of FT's cellular effects, metabolism and kinetics have
shown that FT does not have any effects on nearby structures or on important
distant organs. Repeated injections of FT do not induce any discernible immune
reaction in patients which is another important reason for FT's excellent
safety results.
Google topsalysin then go to the manufacturer's website. They have a video of how their drug works